{"id":"desonide-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Desonide is a low-to-medium potency corticosteroid that works by activating glucocorticoid receptors in skin cells, leading to decreased production of inflammatory mediators and reduced immune cell infiltration. This results in decreased erythema, pruritus, and other inflammatory skin manifestations. It is applied topically and has minimal systemic absorption.","oneSentence":"Desonide is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:07.266Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis)"}]},"trialDetails":[{"nctId":"NCT03437005","phase":"PHASE1","title":"Alternation in the Human Microbiome With Commonly Used Topical Medications","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2013-01-28","conditions":"Healthy","enrollment":24},{"nctId":"NCT03386032","phase":"PHASE3","title":"8-Week Atopic Dermatitis (AD) Treatment Study","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2017-11-27","conditions":"Atopic Dermatitis Eczema","enrollment":65},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT00828412","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2009-03","conditions":"Atopic Dermatitis","enrollment":100},{"nctId":"NCT02732314","phase":"PHASE4","title":"Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Procter & Gamble Beauty","startDate":"2016-03","conditions":"Dermatitis, Atopic, Eczema","enrollment":53},{"nctId":"NCT02286700","phase":"PHASE3","title":"Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis","status":"UNKNOWN","sponsor":"NeoStrata Company, Inc.","startDate":"2014-11","conditions":"Dermatitis, Atopic, Eczema","enrollment":42},{"nctId":"NCT01935310","phase":"NA","title":"Photoaging Treatment With Imiquimod","status":"COMPLETED","sponsor":"CES University","startDate":"2010-07","conditions":"Photoaging","enrollment":17},{"nctId":"NCT01467362","phase":"PHASE3","title":"Efficacy Emollient on Xerosis in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2011-11","conditions":"Atopic Dermatitis","enrollment":251},{"nctId":"NCT01542138","phase":"PHASE4","title":"Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2011-07","conditions":"Hyperpigmentation","enrollment":28}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"RASH"},{"count":9,"reaction":"DRUG INEFFECTIVE"},{"count":9,"reaction":"PRURITUS"},{"count":7,"reaction":"ERYTHEMA"},{"count":4,"reaction":"APPLICATION SITE PAIN"},{"count":4,"reaction":"DIARRHOEA"},{"count":4,"reaction":"DIZZINESS"},{"count":4,"reaction":"DRUG EFFECTIVE FOR UNAPPROVED INDICATION"},{"count":4,"reaction":"DRY SKIN"},{"count":4,"reaction":"FATIGUE"}],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Desonide Cream 0.05%"],"phase":"phase_3","status":"active","brandName":"Desonide Cream","genericName":"Desonide Cream","companyName":"NeoStrata Company, Inc.","companyId":"neostrata-company-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desonide is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}